Lessons learned from genetic testing

JAMA

Volumn 304, Issue 9, 2010, Pages 1011-1012

  Esserman, Laura ^a   Kaklamani, Virginia ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; BIOLOGICAL MARKER;

BREAST CANCER; CANCER RISK; EDITORIAL; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; LAPAROSCOPIC SURGERY; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; BREAST TUMOR; DECISION MAKING; FEMALE; GENETICS; NOTE; OVARIECTOMY; OVARY TUMOR; RISK; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MASTECTOMY; OVARIAN NEOPLASMS; OVARIECTOMY; RISK;

EID: 77956209226     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1263     Document Type: Editorial

References (14)

1. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
2. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update. J Clin Oncol. 2010;28(5):893-901.
3. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment. J Natl Compr Canc Netw. 2010;8(5):562-594.
4. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701-2712.
5. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women. JAMA. 2005;294(15):1925-1933.
6. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-437.
7. Rabban JT, Barnes M, Chen LM, et al. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009;33(8):1125-1136.
8. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol. 2009;113(5):1027-1037.
9. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2005;23(31):7804-7810.
10. Garwood ER, Moore D, Ewing C, et al. Total skin-sparing mastectomy. Ann Surg. 2009;249(1):26-32.
11. Sagi M, Weinberg N, Eilat A, et al. Preimplantation genetic diagnosis for BRCA1/2. Prenat Diagn. 2009;29(5):508-513.
12. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008;8(4):363-369.
13. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
14. The Genetic Information Nondiscrimination Act of 2008, Pub L No. 110-233, 122 Stat 881 (enacted May 21, 2008).